GLP1R and Parkinson disease: Several clinical investigations have reported that DPP4-i and GLP1R agonists were associated with reduced risk of PD (92, 96, 97) and also a beneficial role in frailty status have been associated with GLP1R agonists and sodium-glucose cotransporter 2 (SLGT2) inhibitors (128, 146).